New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
08:05 EDTPLXProtalix CEO David Aviezer to retire this year
Protalix BioTherapeutics announced that David Aviezer, Ph.D., has decided to retire from his role as the company's President and CEO. He will retire this year upon the completion of a process to nominate his successor. In the meantime, Dr. Aviezer will continue serving as President and CEO and remains a member of the Board of Directors. The company's Board of Directors will appoint a committee to select a new CEO.
News For PLX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 16, 2015
09:19 EDTPLXOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
07:06 EDTPLXProtalix to conduct Phase III clinical trial for PRX-102
Subscribe for More Information
November 13, 2015
16:08 EDTPLXProtalix files $100M mixed securities shelf
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use